NeuBase Announces Formation of Gene Editing Advisory Board - Seite 3

Eriks Rozners, Ph.D.

Dr. Rozners is a leading expert in the chemistry and biochemistry of nucleic acids and brings his expertise to NeuBase as the Company is optimizing and developing its PATrOL platform. He is a professor and the chairman of the Department of Chemistry at Binghamton University, where his lab focuses on the use of organic chemistry to develop unique model systems and tools for the studies and practical applications of nucleic acid biochemistry. Dr. Rozners received a bachelor’s degree in chemical engineering and a doctorate in organic chemistry from Riga Technical University.

Jeremy Stark, Ph.D.

Jeremy Stark, Ph.D. received his doctorate at the University of Washington/Fred Hutchinson Cancer Research Center working on RNA splicing, and his postdoctoral training was at Memorial Sloan Kettering Cancer Center with Dr. Maria Jasin, where he began his research on chromosomal break repair and gene editing. He has continued this research focus in his own lab at the City of Hope, where he is now professor of cancer genetics and epigenetics. His research group has developed a series of chromosomal break reporter assays that have been used by several labs around the world. His lab was the first to combine the TREX2 exonuclease with a targeted DSB to cause elevated indel frequencies (Bennardo et al. 2009), leading later to a patent on combining TREX2 and CAS9. Focusing on recent discoveries, his group developed a highly specific assay for canonical non-homologous end joining (C-NHEJ): EJ between two Cas9-induced blunt DSBs without insertion/deletion (indel) mutations (No Indel EJ). This hallmark of C-NHEJ enabled defining key distinctions between this pathway and ALT-EJ, characterizing the function of the C-NHEJ factor XLF (Bhargava et al. 2018), and defining the influence of XLF and DNAPKcs on EJ (Cisneros-Aguirre et al. 2022).

The Company’s recently appointed strategy and business advisors include:

Jeffrey Kindler, J.D.

Jeff Kindler, J.D. is a healthcare executive, investor and advisor who has held leadership positions at numerous globally recognized companies, including Pfizer, McDonald’s and General Electric. With more than three decades of experience, Mr. Kindler is a leading expert in pharmaceuticals and other healthcare sectors, retail, corporate legal matters including regulation, litigation, compliance, and crisis management, brand and franchise management, and executive leadership. Mr. Kindler serves as CEO of Centrexion Corporation, a privately held biotherapeutics company. He is a Senior Advisor for Blackstone, a Venture Partner at Artis Ventures, and a principal in and advisor to numerous privately held healthcare firms and sponsors. Mr. Kindler serves on the boards of several publicly and privately held healthcare companies as well as several not-for-profit institutions.